POM-V Prescription Required

Danilon Equidos Gold 1.5 g Granules for Horses and Ponies

Active ingredient: Suxibuzone

Form

Powder

Species

Horses

Manufacturer

Ecuphar Veterinaria S.L.U.

VMD MA No.

46037/4006

What it's used for

Treatment of pain and inflammation associated with musculo-skeletal conditions in the horse

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Suxibuzone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Danilon Equidos Gold 1.5 g Granules for Horses and Ponies — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Treatment of pain and inflammation associated with musculo-skeletal conditions in
the horse

For oral administration.
When added to a portion of feed the product will be accepted by most horses.
The following should be used as a guide, according to individual response:
Horses
For a 480 kg bodyweight horse, the contents of 2 sachets should be administered
twice daily (equivalent to 12.5 mg of suxibuzone/kg/day) for 2 days, followed by
1 sachet twice daily (6.25 mg of suxibuzone/kg/day) for 3 days.
Thereafter, 1 sachet daily (3.1 mg of suxibuzone/kg/day) or on alternate days, or the
minimum dose frequency necessary for a satisfactory clinical response.
Ponies
Ponies should receive only half the dose rate recommended for horses.
For a 240 kg bodyweight pony, the contents of 1 sachet should be administered daily
(equivalent to 6.25 mg of suxibuzone/kg/day) for 2 days, followed by 1 sachet on
alternate days.
Thereafter, reduce to the minimum dose frequency necessary for a satisfactory clinical
response.
Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of
clinical effect. It is advisable not to feed hay immediately prior to, or with the veterinary
medicinal product.
See also 4.5.
If no clinical response is evident after 4-5 days, discontinue treatment and reconsider
the diagnosis.
Part sachets should not be used.

Do not use in animals with renal, hepatic or cardiac disorders.
Do not use in animals where there is the possibility of gastro-intestinal ulceration or
bleeding.
Do not use in animals where there is evidence of a blood dyscrasia.
Do not use in known cases of hypersensitivity to the active substance or any of the
excipient

After continued use, or at high doses gastro-intestinal changes may occur (very rare
frequency). With a very rare frequency blood dyscrasias and renal alterations may be
found, especially in animals with restricted access to water.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

NSAIDs can cause inhibition of phagocytosis and hence, in the treatment of
inflammatory conditions associated with bacterial infections appropriate antimicrobial
therapy should be instigated.

Revised: January 2025
AN: 02827/2024

Special precautions for use in animals
Do not exceed the stated dose or duration of treatment. Dosage should be kept to a
minimum for alleviation of symptoms.
During treatment of very young animals (less than 12 weeks) where development of
their hepatic or renal function may be incomplete, or in aged animals which may have
these functions impaired, as well as in ponies, additional risk may be involved. In
these cases, the posology should be adjusted and patients monitored closely.
During treatment, do not restrict the consumption of water. Avoid use in any
dehydrated, hypovolaemic or hypotensive animals as there may be an increased risk
of renal failure.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Tartrazine may cause allergic reactions
In case of known hypersensitivity to suxibuzone or any of the excipients, avoid
contact with the product.
Wash hands after use.
Use in a well-ventilated area. To avoid exposure to the granules, part-sachets
should not be used. Avoid inhaling any dust when opening sachet and mixing with
feed. Avoid contact with skin, eyes and mucosa. In case of accidental contact, wash
with plenty of clean water. In case of accidental ingestion, seek medical advice
immediately and show this label to the physician.

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete
with other highly bound drugs eg sulphonamides, warfarin; or it may itself be displaced
to produce an increase of non-bound pharmacologically active concentrations which
could lead to toxic effects. Drug compatibility must be closely monitored when
adjunctive therapy is required.

Revised: January 2025
AN: 02827/2024
Do not administer together with other NSAIDs concurrently or within 24 hours of each
other.
Concurrent administration of potentially nephrotoxic drugs should be avoided.

This veterinary medicinal product does not require any special storage conditions.

If no clinical response is evident after 4-5 days, discontinue treatment and reconsider
the diagnosis.
Part sachets should not be used.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of accidental continuous overdose, the following symptoms may be observed:
•
•
•
•
shock and circulatory collapse.
•
If signs of intolerance appear, discontinue treatment and establish symptomatic
therapy.
A slow intravenous perfusion of a solution of sodium bicarbonate, which leads to urine
alkalinisation, increases the clearance of the product.

Revised: January 2025
AN: 02827/2024
4.11 Withdrawal period
Not to be used in animals intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under
national horse passport legislation.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.